Parenteral artesunate access programme aims at reducing malaria fatality rates in South Africa

Parenteral artesunate should be used in preference to quinine for the treatment of severe malaria, given its significant mortality and safety benefits. As the product has not yet been registered for use in South Africa, the Parenteral Artesunate Access Programme has been launched to reduce malaria-r...

Full description

Saved in:
Bibliographic Details
Published in:South African medical journal 2011-04, Vol.101 (4), p.240-241
Main Authors: Kift, E Visser, Kredo, T, Barnes, K I
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antimalarials - administration & dosage
Antimalarials - therapeutic use
Artemisinins - administration & dosage
Artemisinins - therapeutic use
Drug therapy
Female
Health aspects
Health Services Accessibility - organization & administration
Humans
Infusions, Parenteral
Malaria
Malaria - mortality
Male
Middle Aged
Mortality
Prevention
South Africa
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parenteral artesunate should be used in preference to quinine for the treatment of severe malaria, given its significant mortality and safety benefits. As the product has not yet been registered for use in South Africa, the Parenteral Artesunate Access Programme has been launched to reduce malaria-related mortality. Severe malaria is a medical emergency that requires prompt treatment to prevent death, which occurs in 10 - 50% of patients. super(1) Based on high-quality evidence, the World Health Organization (WHO) now strongly recommends intravenous (IV) artesunate in preference to IV quinine for the treatment of severe malaria in adults. super(2).
ISSN:0256-9574
DOI:10.7196/samj.4761